Sanofi SA (SASY)

94.08 +0.25 (+0.27%)
Closed EUR Disclaimer

Sanofi SA Company Profile

Equity Type
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Contact Information
Paris,75017 France
33 1 53 77 40 00
Top Executives
Serge Weinberg 73 2009 Honorary Chairman
Jean-François Dehecq 84 1982 Honorary Chairman
Fabienne Lecorvaisier 62 2013 Independent Director
Patrick Kron 71 2014 Independent Director
Paul Hudson 57 2019 CEO & Director
Gilles Schnepp 66 2021 Independent Director
Frederic Oudea 61 2022 Independent Chairman
Lise Kingo 63 2020 Independent Director
Ceng-Yann Tran 59 2021 Employee Representative Director
Christophe Babule 59 2019 Director
Carole Ferrand 54 2022 Independent Director
Barbara Lavernos 56 2021 Director
Wolfgang Laux 56 2021 Employee Representative Director
Rachel Duan 54 2020 Independent Director
Antoine Yver 66 2022 Independent Director
Emile Voest 65 2022 Independent Director
Clotilde Delbos 57 2024 Independent Director
Anne-Francoise Michele Nesmes Rankine 52 2024 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.